<p>蒙特利爾，魁北克 --（Newsfile Corp. -2026 年 1 月 21 日）- Defence Therapeutics Inc.（CSE: DTC）（FSE: DTC）（OTCQB: DTCFF）（“Defence” 或 “公司”），一家上市生物技術公司，今天宣佈其企業定位的演變，以反映其作為一家精確細胞內藥物遞送公司的專注，正在通過內部開發項目和戰略合作伙伴關係推進其專有的 Accum®平台。Accum®旨在釋放複雜癌症生物製劑的全部潛力，增強細胞內遞送以提高治療效力，同時降低毒性。</p>
<p>這一戰略的核心是 Accum®，Defence Therapeutics 的專有精確藥物遞送平台，旨在解決腫瘤學中最持久的挑戰之一：有效的細胞內遞送。通過增強細胞攝取和藥物釋放，Accum®在較低劑量下提高治療效力，有潛力減少毒性並改善患者對先進癌症治療的獲取。</p>
<p>Defence 正在通過一種雙重戰略優先考慮這一平台和合作模式，該戰略結合了內部研發項目與生物技術和製藥生態系統中的戰略合作伙伴關係。這種方法使得現有資產和下一代資產的增強成為可能，包括抗體藥物偶聯物（ADCs）、放射藥物和其他複雜生物製劑，將傳統上用於後期治療的療法轉變為更安全、更有效的一線治療選擇。</p>
<p>“我們的重點很明確：解決細胞層面的藥物遞送，以便無論是由 Defence 開發還是由我們的合作伙伴開發的癌症療法，都能發揮其全部潛力，” Defence Therapeutics 首席執行官 Sébastien Plouffe 表示。“Accum®旨在為合作伙伴創造最佳價值，同時最終為患者提供更好的治療結果。”</p>
<p>通過這一精煉的定位，Defence Therapeutics 重申了其對精準腫瘤學、合作和將前沿科學轉化為改變生命的治療的承諾，其商業模式旨在為合作伙伴創造可擴展的價值，併為股東創造長期價值。要了解更多信息或探索合作機會，請訪問 <strong>www.defencetherapeutics.com</strong> 或聯繫 <strong>info@defencetherapeutics.com</strong>。</p>
<p><strong>關於 Defence Therapeutics：</strong></p>
<p>Defence Therapeutics 是一家上市生物技術公司，致力於使癌症治療更有效和更安全。通過其 Accum®精確藥物遞送平台，Defence 正在努力提高抗體藥物偶聯物（ADCs）和其他複雜生物製劑在較低劑量下的效力，目標是減少副作用並改善對先進療法的獲取。通過追求前沿科學，並與製藥和生物技術合作伙伴合作，Defence 努力為最需要的患者帶來變革性療法。要了解更多關於 Defence Therapeutics 的信息並探索合作機會，請訪問 www.defencetherapeutics.com 或聯繫 info@defencetherapeutics.com。</p>
<p>如需更多信息：</p>
<p>Sébastien Plouffe</p>
<p>首席執行官、創始人及董事</p>
<p>電話：（514）947-2272</p>
<p>Splouffe@defencetherapeutics.com</p>
<p>www.defencetherapeutics.com</p>
<p><strong>關於 “前瞻性” 信息的警示聲明</strong></p>
<p>本發佈包含某些可能被視為 “前瞻性聲明” 的內容。除歷史事實外，本發佈中的所有聲明，涉及公司預期發生的事件或發展，均為前瞻性聲明。前瞻性聲明是指非歷史事實的聲明，通常但不總是通過 “預期”、“計劃”、“預計”、“相信”、“打算”、“估計”、“項目”、“潛在” 等詞語或 “將”、“會”、“可能”、“能夠” 或 “應該” 發生的事件或條件來識別。儘管公司相信這些前瞻性聲明中表達的預期基於合理假設，但這些聲明並不保證未來的表現，實際結果可能與前瞻性聲明中的結果有實質性差異。可能導致實際結果與前瞻性聲明中的結果有實質性差異的因素包括監管行動、市場價格、資本和融資的持續可用性，以及一般經濟、市場或商業條件。投資者被警告，任何此類聲明並不保證未來的表現，實際結果或發展可能與前瞻性聲明中預測的結果有實質性差異。前瞻性聲明基於公司管理層在聲明發布時的信念、估計和意見。除非適用證券法要求，否則公司不承擔在管理層的信念、估計或意見或其他因素髮生變化時更新這些前瞻性聲明的義務。</p>
<p>CSE 及其市場監管機構（根據 CSE 政策中的定義）對本發佈的充分性或準確性不承擔責任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/280931_8f462d43e4ade8b1_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/280931_8f462d43e4ade8b1_logo.jpg"/></p>
<p>要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/280931</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/280931/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/280931/375"/></p>

<p>Defence Therapeutics Inc. 宣佈戰略轉型，專注於其 Accum® 精準藥物遞送平台，旨在提高癌症生物製劑的有效性。該公司計劃通過內部開發和戰略合作推進這一平台，目標是提高治療效力並降低毒性。首席執行官 Sébastien Plouffe 強調了優化藥物遞送以最大化患者治療效果的目標。這一精細化戰略突顯了 Defence 對精準腫瘤學的承諾，以及在生物科技生態系統內的合作，旨在為患者提供變革性的治療</p>

<p>Montreal, Quebec--(Newsfile Corp. - January 21, 2026) - Defence Therapeutics Inc., (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (&#34;Defence&#34; or the &#34;Company&#34;), a publicly traded biotechnology company, today announced an evolution of its corporate positioning to reflect its focus as a precision intracellular drug-delivery company advancing its proprietary Accum® platform through both internal development programs and strategic partnerships. Designed to unlock the full potential of complex cancer biologics, Accum® enhances intracellular delivery to increase therapeutic potency while reducing toxicity.</p>
<div class="lb-trans"><p>蒙特利爾，魁北克 --（Newsfile Corp. -2026 年 1 月 21 日）- Defence Therapeutics Inc.（CSE: DTC）（FSE: DTC）（OTCQB: DTCFF）（“Defence” 或 “公司”），一家上市生物技術公司，今天宣佈其企業定位的演變，以反映其作為一家精確細胞內藥物遞送公司的專注，正在通過內部開發項目和戰略合作伙伴關係推進其專有的 Accum®平台。Accum®旨在釋放複雜癌症生物製劑的全部潛力，增強細胞內遞送以提高治療效力，同時降低毒性。</p>
</div><p>At the center of this strategy is Accum®, Defence Therapeutics' proprietary precision drug-delivery platform designed to solve one of oncology's most persistent challenges: effective intracellular delivery. By enhancing cellular uptake and payload release, Accum® increases therapeutic potency at lower doses, with the potential to reduce toxicity and improve patient access to advanced cancer treatments.</p>
<div class="lb-trans"><p>這一戰略的核心是 Accum®，Defence Therapeutics 的專有精確藥物遞送平台，旨在解決腫瘤學中最持久的挑戰之一：有效的細胞內遞送。通過增強細胞攝取和藥物釋放，Accum®在較低劑量下提高治療效力，有潛力減少毒性並改善患者對先進癌症治療的獲取。</p>
</div><p>Defence is prioritizing this platform and partnering model through a dual strategy that combines internal R&amp;D programs with strategic partnerships across the biotech and pharmaceutical ecosystem. This approach enables the enhancement of both existing and next-generation assets, including antibody-drug conjugates (ADCs), radiopharmaceuticals, and other complex biologics, transforming therapies traditionally used in later lines into safer, more effective first-line treatment options.</p>
<div class="lb-trans"><p>Defence 正在通過一種雙重戰略優先考慮這一平台和合作模式，該戰略結合了內部研發項目與生物技術和製藥生態系統中的戰略合作伙伴關係。這種方法使得現有資產和下一代資產的增強成為可能，包括抗體藥物偶聯物（ADCs）、放射藥物和其他複雜生物製劑，將傳統上用於後期治療的療法轉變為更安全、更有效的一線治療選擇。</p>
</div><p>&#34;Our focus is clear: solve drug delivery at the cellular level so cancer therapies, whether developed by Defence or by our partners, can reach their full potential,&#34; said Sébastien Plouffe, CEO of Defence Therapeutics. &#34;Accum® is designed to create optimal value for partners while ultimately delivering better outcomes for patients.&#34;</p>
<div class="lb-trans"><p>“我們的重點很明確：解決細胞層面的藥物遞送，以便無論是由 Defence 開發還是由我們的合作伙伴開發的癌症療法，都能發揮其全部潛力，” Defence Therapeutics 首席執行官 Sébastien Plouffe 表示。“Accum®旨在為合作伙伴創造最佳價值，同時最終為患者提供更好的治療結果。”</p>
</div><p>With this refined positioning, Defence Therapeutics reinforces its commitment to precision oncology, collaboration, and translating cutting-edge science into life-changing treatments, with a business model designed to generate scalable value for partners and long-term value for shareholders. To learn more or explore partnering opportunities, please visit <strong>www.defencetherapeutics.com</strong> or contact <strong>info@defencetherapeutics.com</strong>.</p>
<div class="lb-trans"><p>通過這一精煉的定位，Defence Therapeutics 重申了其對精準腫瘤學、合作和將前沿科學轉化為改變生命的治療的承諾，其商業模式旨在為合作伙伴創造可擴展的價值，併為股東創造長期價值。要了解更多信息或探索合作機會，請訪問 <strong>www.defencetherapeutics.com</strong> 或聯繫 <strong>info@defencetherapeutics.com</strong>。</p>
</div><p><strong>About Defence Therapeutics:</strong></p>
<div class="lb-trans"><p><strong>關於 Defence Therapeutics：</strong></p>
</div><p>Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.</p>
<div class="lb-trans"><p>Defence Therapeutics 是一家上市生物技術公司，致力於使癌症治療更有效和更安全。通過其 Accum®精確藥物遞送平台，Defence 正在努力提高抗體藥物偶聯物（ADCs）和其他複雜生物製劑在較低劑量下的效力，目標是減少副作用並改善對先進療法的獲取。通過追求前沿科學，並與製藥和生物技術合作伙伴合作，Defence 努力為最需要的患者帶來變革性療法。要了解更多關於 Defence Therapeutics 的信息並探索合作機會，請訪問 www.defencetherapeutics.com 或聯繫 info@defencetherapeutics.com。</p>
</div><p>For further information:</p>
<div class="lb-trans"><p>如需更多信息：</p>
</div><p>Sebastien Plouffe</p>
<div class="lb-trans"><p>Sébastien Plouffe</p>
</div><p>CEO, Founder and Director</p>
<div class="lb-trans"><p>首席執行官、創始人及董事</p>
</div><p>P: (514) 947-2272</p>
<div class="lb-trans"><p>電話：（514）947-2272</p>
</div><p>Splouffe@defencetherapeutics.com</p>
<div class="lb-trans"><p>Splouffe@defencetherapeutics.com</p>
</div><p>www.defencetherapeutics.com</p>
<div class="lb-trans"><p>www.defencetherapeutics.com</p>
</div><p><strong>Cautionary Statement Regarding &#34;Forward-Looking&#34; Information</strong></p>
<div class="lb-trans"><p><strong>關於 “前瞻性” 信息的警示聲明</strong></p>
</div><p>This release includes certain statements that may be deemed &#34;forward-looking statements&#34;. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words &#34;expects&#34;, &#34;plans&#34;, &#34;anticipates&#34;, &#34;believes&#34;, &#34;intends&#34;, &#34;estimates&#34;, &#34;projects&#34;, &#34;potential&#34; and similar expressions, or that events or conditions &#34;will&#34;, &#34;would&#34;, &#34;may&#34;, &#34;could&#34; or &#34;should&#34; occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.</p>
<div class="lb-trans"><p>本發佈包含某些可能被視為 “前瞻性聲明” 的內容。除歷史事實外，本發佈中的所有聲明，涉及公司預期發生的事件或發展，均為前瞻性聲明。前瞻性聲明是指非歷史事實的聲明，通常但不總是通過 “預期”、“計劃”、“預計”、“相信”、“打算”、“估計”、“項目”、“潛在” 等詞語或 “將”、“會”、“可能”、“能夠” 或 “應該” 發生的事件或條件來識別。儘管公司相信這些前瞻性聲明中表達的預期基於合理假設，但這些聲明並不保證未來的表現，實際結果可能與前瞻性聲明中的結果有實質性差異。可能導致實際結果與前瞻性聲明中的結果有實質性差異的因素包括監管行動、市場價格、資本和融資的持續可用性，以及一般經濟、市場或商業條件。投資者被警告，任何此類聲明並不保證未來的表現，實際結果或發展可能與前瞻性聲明中預測的結果有實質性差異。前瞻性聲明基於公司管理層在聲明發布時的信念、估計和意見。除非適用證券法要求，否則公司不承擔在管理層的信念、估計或意見或其他因素髮生變化時更新這些前瞻性聲明的義務。</p>
</div><p>Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.</p>
<div class="lb-trans"><p>CSE 及其市場監管機構（根據 CSE 政策中的定義）對本發佈的充分性或準確性不承擔責任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/280931_8f462d43e4ade8b1_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/8000/280931_8f462d43e4ade8b1_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280931</p>
<div class="lb-trans"><p>要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/280931</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/280931/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/280931/375"/></p>

Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics | DTCFF Stock News

StockTitan

醫療業 ETF - Vanguard

動態生物技術與基因組 ETF - Invesco

醫藥突破 ETF - ALPS

ESC NEUBASE THERAPEUTI

Black Diamond Therapeutics

美國制藥 ETF - iShares

2 倍做多納斯達克生物技術 ETF - ProShares

納斯達克生物科技指數 ETF - iShares Nasdaq

紐交所高增長板生物技術指數 ETF - First Trust

基因改革 ETF - ARK

標普生物技術 ETF - SPDR

生物科技 ETF - VanEck Vectors

Turn Therapeutics

Defence Therapeutics 聚焦於精準藥物遞送，旨在充分發揮癌症生物製劑的潛力 | DTCFF 股票新聞